Korean Journal of Ophthalmology

The Korean Ophthalmological Society (대한안과학회)
권호 표지
DOI QR코드

DOI QR Code

Efficacy and Safety of Intracameral Bevacizumab for Treatment of Neovascular Glaucoma

  • Ha, Jun Young (Department of Ophthalmology and Research Institute of Medical Sciences, Chonnam National University Hospital, Chonnam National University Medical School) ;
  • Lee, Tae Hee (Department of Ophthalmology and Research Institute of Medical Sciences, Chonnam National University Hospital, Chonnam National University Medical School) ;
  • Sung, Mi Sun (Department of Ophthalmology and Research Institute of Medical Sciences, Chonnam National University Hospital, Chonnam National University Medical School) ;
  • Park, Sang Woo (Department of Ophthalmology and Research Institute of Medical Sciences, Chonnam National University Hospital, Chonnam National University Medical School)
  • Received : 2017.01.31
  • Accepted : 2017.05.10
  • Published : 2017.12.05
⟨ Previous Next ⟩

Abstract

Purpose: To evaluate the long-term efficacy and safety of intracameral bevacizumab in patients with neovascular glaucoma. Methods: This retrospective study included 26 eyes of 26 neovascular glaucoma patients who received intracameral bevacizumab injection between January 2013 and May 2015, and were followed-up for at least 1 year. All patients were treated with topical and/or systemic intraocular pressure (IOP)-lowering medications, intracameral bevacizumab, and panretinal photocoagulation (PRP). The main outcome measures were changes in visual acuity, IOP, and neovascularization of the iris (NVI) and the anterior chamber angle (NVA). To assess the safety of intracameral bevacizumab, corneal endothelial changes were also determined using specular microscopy. Patients whose IOP was uncontrolled received IOP-lowering surgery. Clinical factors associated with IOP-lowering surgery were also investigated. Results: In all patients, intracameral bevacizumab resulted in a rapid and marked reduction of IOP, NVI, and NVA within 1 week. At 12 months after initial injection, 19 of 26 eyes (73%) underwent IOP-lowering surgery. The average interval between initial injection and surgical treatment was $33.6{\pm}26.9days$. Baseline IOP (p = 0.018), NVA grade (p = 0.029), and incomplete PRP (p = 0.005) were identified as predictive factors for IOP-lowering surgery. During the follow-up period, there were no statistically significant corneal endothelial changes after intracameral bevacizumab injection. Conclusions: During 1 year of follow-up after intracameral bevacizumab, the procedure was found to be safe for the corneal endothelium. However, the IOP-lowering effect was transient, and 73% of patients eventually required IOP-lowering surgery. Predictive factors for IOP-lowering surgery were high baseline IOP and NVA grade, and incomplete PRP.

Keywords

References

  1. Shazly TA, Latina MA. Neovascular glaucoma: etiology, diagnosis and prognosis. Semin Ophthalmol 2009;24:113-21. https://doi.org/10.1080/08820530902800801
  2. Sivak-Callcott JA, O'Day DM, Gass JD, Tsai JC. Evidencebased recommendations for the diagnosis and treatment of neovascular glaucoma. Ophthalmology 2001;108:1767-76. https://doi.org/10.1016/S0161-6420(01)00775-8
  3. Doft BH, Blankenship G. Retinopathy risk factor regression after laser panretinal photocoagulation for proliferative diabetic retinopathy. Ophthalmology 1984;91:1453-7. https://doi.org/10.1016/S0161-6420(84)34123-9
  4. Aiello LP, Avery RL, Arrigg PG, et al. Vascular endothelial growth factor in ocular fluid of patients with diabetic retinopathy and other retinal disorders. N Engl J Med 1994;331:1480-7. https://doi.org/10.1056/NEJM199412013312203
  5. Tripathi RC, Li J, Tripathi BJ, et al. Increased level of vascular endothelial growth factor in aqueous humor of patients with neovascular glaucoma. Ophthalmology 1998;105:232-7. https://doi.org/10.1016/S0161-6420(98)92782-8
  6. Sasamoto Y, Oshima Y, Miki A, et al. Clinical outcomes and changes in aqueous vascular endothelial growth factor levels after intravitreal bevacizumab for iris neovascularization and neovascular glaucoma: a retrospective twodose comparative study. J Ocul Pharmacol Ther 2012;28:41-8. https://doi.org/10.1089/jop.2011.0059
  7. Boyd SR, Zachary I, Chakravarthy U, et al. Correlation of increased vascular endothelial growth factor with neovascularization and permeability in ischemic central vein occlusion. Arch Ophthalmol 2002;120:1644-50. https://doi.org/10.1001/archopht.120.12.1644
  8. Ehlers JP, Spirn MJ, Lam A, et al. Combination intravitreal bevacizumab/panretinal photocoagulation versus panretinal photocoagulation alone in the treatment of neovascular glaucoma. Retina 2008;28:696-702. https://doi.org/10.1097/IAE.0b013e3181679c0b
  9. Wolf A, von Jagow B, Ulbig M, Haritoglou C. Intracameral injection of bevacizumab for the treatment of neovascular glaucoma. Ophthalmologica 2011;226:51-6. https://doi.org/10.1159/000327364
  10. Krohne TU, Eter N, Holz FG, Meyer CH. Intraocular pharmacokinetics of bevacizumab after a single intravitreal injection in humans. Am J Ophthalmol 2008;146:508-12. https://doi.org/10.1016/j.ajo.2008.05.036
  11. Yazdani S, Hendi K, Pakravan M, et al. Intravitreal bevacizumab for neovascular glaucoma: a randomized controlled trial. J Glaucoma 2009;18:632-7. https://doi.org/10.1097/IJG.0b013e3181997211
  12. Wakabayashi T, Oshima Y, Sakaguchi H, et al. Intravitreal bevacizumab to treat iris neovascularization and neovascular glaucoma secondary to ischemic retinal diseases in 41 consecutive cases. Ophthalmology 2008;115:1571-80. https://doi.org/10.1016/j.ophtha.2008.02.026
  13. Weiss DI, Gold D. Neofibrovascularization of iris and anterior chamber angle: a clinical classification. Ann Ophthalmol 1978;10:488-91.
  14. Fleiss JL. Statistical methods for rates and proportions. 2nd ed. New York: John Wiley and Sons; 1981. p. 212-3.
  15. Sugimoto Y, Mochizuki H, Okumichi H, et al. Effect of intravitreal bevacizumab on iris vessels in neovascular glaucoma patients. Graefes Arch Clin Exp Ophthalmol 2010; 248:1601-9. https://doi.org/10.1007/s00417-010-1406-x
  16. Bhagat PR, Agrawal KU, Tandel D. Study of the effect of injection bevacizumab through various routes in neovascular glaucoma. J Curr Glaucoma Pract 2016;10:39-48.
  17. Yazdani S, Hendi K, Pakravan M. Intravitreal bevacizumab (Avastin) injection for neovascular glaucoma. J Glaucoma 2007;16:437-9. https://doi.org/10.1097/IJG.0b013e3180457c47
  18. Kotecha A, Spratt A, Ogunbowale L, et al. Intravitreal bevacizumab in refractory neovascular glaucoma: a prospective, observational case series. Arch Ophthalmol 2011;129: 145-50. https://doi.org/10.1001/archophthalmol.2010.350
  19. Nakano S, Nakamuro T, Yokoyama K, et al. Prognostic factor analysis of intraocular pressure with neovascular glaucoma. J Ophthalmol 2016;2016:1205895.
  20. Hosny MH, Zayed MA, Shalaby AM, Eissa IM. Effect of intracameral bevacizumab injection on corneal endothelial cells: an in vivo evaluation. J Ocul Pharmacol Ther 2009; 25:513-7. https://doi.org/10.1089/jop.2009.0056
  21. Park HY, Kim SJ, Lee HB, et al. Effect of intracameral bevacizumab injection on corneal endothelium in rabbits. Cornea 2008;27:1151-5. https://doi.org/10.1097/ICO.0b013e318180e572

Cited by

  1. A Pilot Clinical Study of Intravitreal Injection of Artesunate for Ocular Neovascularization vol.35, pp.5, 2019, https://doi.org/10.1089/jop.2018.0097
  2. Intravitreal Bevacizumab for Inflammatory Neovascularization of the Lens after Traumatic Open Globe Injury vol.28, pp.4, 2017, https://doi.org/10.1080/09273948.2019.1609048
  3. Aqueous Inflammation and Ischemia-Related Biomarkers in Neovascular Glaucoma with Stable Iris Neovascularization vol.45, pp.12, 2017, https://doi.org/10.1080/02713683.2020.1762226